Proplatelet production represents a terminal stage of megakaryocyte development during which long, branching processes comprised of platelet-sized swellings are extended and released into the surrounding culture. While the cytoskeletal mechanics driving these transformations have been the focus of many studies, significant limitations in our ability to quantify the rate and extent of proplatelet production have restricted the field to qualitative analyses of limited numbers of cells over short intervals. A novel high-content, quantitative, live-cell imaging assay using the Incucyte system was therefore developed to measure the rate and extent of megakaryocyte maturation and proplatelet production under live culture conditions for extended periods of time. As proof of concept we use this system to establish a mechanism by which trastuzumab emtansine (T-DM1), an antibody-drug conjugate currently in clinical development for cancer, affects platelet production. High-content analysis of primary cell cultures revealed that T-DM1 is taken up by mouse megakaryocytes, inhibits megakaryocyte differentiation, and disrupts proplatelet formation by inducing abnormal tubulin organization and suppressing microtubule dynamic instability. Defining the pathways by which therapeutics such as T-DM1
Introduction
Platelets are formed and released into the bloodstream by specialized precursor cells called megakaryocytes. During the final stages of development, megakaryocytes remodel their cytoplasm into long, microtubule-based proplatelet extensions from which platelets are produced. Each day an adult produces approximately 100 billion platelets 1 in order to maintain a circulating concentration of 1.5-4 x 10 8 platelets/mL. Platelets are essential for blood clotting, and the rate of platelet production can increase by a factor of 10 or more when the demand for platelets suddenly increases. Conversely, when platelet numbers are very low a patient is at serious risk of death from hemorrhage. Recent efforts to generate useful numbers of clinically viable platelets for infusion by reproducing elements of the bone marrow vascular niche have been met with limited success. 2, 3 Significant improvements in platelet quality and yield will require the ability to empirically assay multiple individual components of the bone marrow microenvironment in high-throughput for quantitative improvements in megakaryocyte maturation and proplatelet production before they are incorporated in scaled bio-mimetic systems.
Drug-induced thrombocytopenia can be triggered by a wide range of medications through the inhibition of megakaryocyte development and platelet biogenesis and/or the clearance of platelets in the blood. 4, 5 Approximately 10 persons per million (in the US and Europe) are affected by drug-induced thrombocytopenia per year, which can range from mild to lifethreatening. 6 The slow recovery of platelet levels in such patients is a serious medical problem and has resulted in a steady increase in demand for platelet transfusions. While platelet survival and clearance rates during drug development are typically measured through infusion studies using flow cytometry, 7 quantification of the rate and extent of proplatelet production is not
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From amenable to this approach, instead requiring direct visualization to establish at what stage thrombocytopoiesis is affected. Mouse primary fetal liver megakaryocyte cultures currently represent the most desirable culture method to study proplatelet production ex vivo, and can be used to test thrombocytopoiesis-related drug effects apart from platelet clearance. 8 Quantification of megakaryocyte differentiation and proplatelet production is complicated by significant limitations in our ability to culture these cells. These include the asynchronous differentiation of hematopoietic stem cells in culture, necessity to visualize cultures over extended periods of time (4 days for mouse, 14 days for human), relatively low number of megakaryocytes generated (<10% of fetal liver cell culture population), asynchronous proplatelet production, and variable resultant cellular morphologies. 9 Practical limitations of imaging megakaryocyte differentiation and proplatelet production have made thresholding individual cells and high-throughput quantification of key stages across multiple experimental parameters in culture even more challenging. Furthermore, light refraction through the meniscus results in uneven background illumination and affects image contrast, high-energy incident light can kill cells during repeated exposure, and the necessity to maintain cells under standard culture conditions makes it impractical to visualize multiple cell culture replicates simultaneously over extended periods of time. As a result, most studies to date have relied on static snapshots of megakaryocyte differentiation from a limited number of timepoints. Live imaging approaches, by comparison, have traditionally yielded mostly qualitative data from a small numbers of cells, and are therefore subject to selection bias.
In this manuscript we describe a novel high-content, quantitative, live-cell imaging assay to measure the rate and extent of megakaryocyte differentiation and proplatelet production in vitro. To demonstrate proof of concept, we then apply this assay to a clinically-relevant case of
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Materials and methods
Reagents. T-DM1, 5B6-DM1 and trastuzumab were provided by Genentech (South San Francisco, CA).
Drug treatment.
Cultured mouse megakaryocytes and mouse/human washed platelets were incubated separately with 100 µg/mL T-DM1, 5B6-DM1 (trastuzumab specificity control), and trastuzumab (antibody control) for up to 72 hrs.
Mouse/human whole blood platelets. Murine blood was obtained by retro-orbital bleed into 0.1 volume Aster-Jandl anticoagulant from anesthetized mice, as previously described. 7 Human blood was obtained by venipuncture from healthy laboratory volunteers, as previously described. 10 Collections were performed in accordance with ethics regulation with Brigham and Women's Hospital IRB approval, and informed consent was provided according to the Declaration of Helsinki.
Megakaryocyte suspension cultures.
Mouse fetal liver cells were collected from CD1 mice (Charles River Laboratories, Wilmington, MA) on embryonic day 13.5, and cultured at 37 °C and 5% CO 2 in the presence of 0.5% tissue culture supernatant from a fibroblast cell line engineered to secrete recombinant human thrombopoietin for 5 days. Round megakaryocytes 
Preparation of Photomicrographs. Digital images were analyzed using ImageJ (NIH).
Dividing lines explicitly separate different images, or separate regions of the same image. No specific features within an image were enhanced, obscured, moved, removed, or introduced, and adjustments made to the brightness, contrast, and color balance were linearly applied to the whole image.
Results
To overcome the major practical limitations of high-throughput imaging of live cells and enable quantification of the rate and extent of megakaryocyte differentiation and proplatelet production from primary mouse cultures we employed the Incucyte HD system with a 20x objective. By placing the microscope inside the incubator the Incucyte system allowed us to collect live cell images of the megakaryocyte cultures at 1 hr. intervals over 72 hrs. The high-definition imaging mode provided by Incucyte uses a combination of changes to the optical path of light and software analysis to eliminate the visual effect caused by refraction of light through the meniscus. This resulted in reduced image halo, improved contrast, and more even background illumination relative to standard phase-contrast imaging. Because the incident light is of low energy and illumination time is minimal due to software-driven focus, this instrument is well suited for live cell imaging over long periods of time. Figure 1A Quantitative analysis of mouse fetal liver cell and round megakaryocyte cultures in Figure 2 represents a major technological advance in our ability to study previously inaccessible kinetics of megakaryocyte cell cultures, and was performed in ImageJ using investigator-coded software (Supplemental Data). Analysis enabled the real-time detection of both the rate and extent of megakaryocyte differentiation and proplatelet production for at least 100 cells over multiple cell culture replicates. Quantification was confirmed by manual counts of megakaryocyte number and percent of proplatelet production, and agreed with previously-published data. 
T-DM1 inhibits megakaryocyte differentiation and proplatelet production
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As proof of concept we used this assay to examine the mechanism of trastuzumab entasinsineinduced thrombocytopenia. T-DM1 is an antibody-drug conjugate currently in clinical development for HER-2-positive cancer that incorporates the intracellular delivery of the potent anti-microtubule agent DM1 with the antitumor properties of the humanized antibody trastuzumab. HER2 is overexpressed in 20% of breast cancers.
14 Human studies of T-DM1 in patients with advanced HER2-positive breast cancer have demonstrated transient thrombocytopenia (<150 000 platelets/µL) as a major side effect in approximately 54% of cases beginning as soon as 1 day after T-DM1 administration, and reaching nadir by approximately Day 8. 15 Of these, 12.5% were of grades 3 and 4 (<50 000 platelets/µL). While these patients received 4.8 mg/kg T-DM1, declines in platelet levels occurred in almost all patients receiving T-DM1 at doses >1.2 mg/kg. 15 Patients in these studies were treated with T-DM1 on a 3-week schedule and platelet numbers were recovered by Day 15, suggesting that T-DM1 may be affecting platelet production.
To determine whether T-DM1 is affecting megakaryocyte differentiation and proplatelet production, mouse fetal liver cell cultures and mature megakaryocytes were incubated with 100 µg/mL T-DM1, 5B6-DM1 (non-specific humanized antibody-drug conjugate control), trastuzumab (antibody alone), or a vehicle control for up to 4 days and analyzed on the Incucyte system using investigator-coded software (Supplemental Data). This represents a physiologically relevant (circulating) concentration of the antibody-drug complex in humans undergoing T-DM1 treatment, and was not toxic to cells in culture. T-DM1 and 5B6-DM1 incubations resulted in complete inhibition of megakaryocyte differentiation (Fig. 3A, Supplementary Video 1) .
Likewise, mature megakaryocytes treated with either T-DM1 or 5B6-DM1 experienced a 6 hr.
delay in proplatelet extension. Delay in proplatelet production has not previously been reported in the literature, and would not have been possible to detect by conventional analysis. Proplatelet production was also significantly reduced in T-DM1-and 5B6-DM1-treated samples and consisted of fewer, unbranched proplatelets per megakaryocyte relative to vehicle control ( Fig.   3B /C, Supplementary Video 2). Trastuzumab alone had no effect on megakaryocyte differentiation or proplatelet production, and suggests that the microtubule-disrupting agent DM1
is causing inhibition. Because proplatelet extension is powered by microtubules we examined microtubule organization during proplatelet production. Cultured mouse megakaryocytes were retrovirally transfected to express EGFP-β1-tubulin and treated with either trastuzumab or T-DM1 (Fig. 3D, Supplementary Video 3 ). Megakaryocytes incubated with T-DM1 showed thicker microtubules relative to trastuzumab control, which was confirmed by quantification of mean fluorescence intensity across the proplatelet shaft. Abnormal tubulin organization and suppressed microtubule dynamic instability in T-DM1-treated megakaryocytes was similar to that observed in MCF7 breast cancer cells treated with both conjugate and free maytansinoids, 16 which suggested that DM1 was disrupting proplatelet formation.
T-DM1 is taken up by mouse megakaryocytes and mouse/human platelets
Megakaryocytes/platelets do not express the HER2 receptor and mice do not contain the Fc γ RIIA receptor for human IgG. 17, 18 Although trastuzumab is a humanized monoclonal antibody directed against the extracellular domain of HER2, our observation that 5B6-DM1 has similar effects to T-DM1 in mouse hematopoietic stem cells and megakaryocyte cultures suggests that drug uptake is HER2-and Fc γ RIIA-receptor independent. To demonstrate that trastuzumab is taken up by mouse megakaryocytes in culture, samples were incubated with either 100 µg/mL T-DM1, 5B6-DM1, trastuzumab, or a vehicle control for up to 24hrs (Fig. 4A ). Megakaryocytes
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From were permeabilized and probed for β 1-tubulin (green) and trastuzumab (red), and analyzed at 63x magnification by immunofluorescence microscopy (Fig. 4B) . Trastuzumab entered megakaryocytes and was detected in both T-DM1-and trastuzumab-treated samples. Conversely, T-DM1 and 5B6-DM1 induced microtubule thickening and reduced proplatelet elongation in megakaryocytes, which confirms that DM1 is affecting microtubule organization in these cells.
Since T-DM1 may also be affecting circulating platelets, mouse and human platelets were isolated from whole blood and incubated with 100 µg/mL T-DM1, 5B6-DM1, trastuzumab or a vehicle control for up to 4 hrs. Platelets were fixed, permeabilized and probed for trastuzumab (red) and analyzed at 20x magnification by immunofluorescence microscopy. 
DM1 disrupts the microtubule cytoskeleton of both megakaryocytes and platelets
Upon endocytosis, T-DM1 is catabolized resulting in the release of the active catabolite, Lys-MCC-DM1. 19, 20 To establish the potential effect of DM1 on cultured mouse megakaryocytes and mouse or human washed platelets independent of trastuzumab, cells were incubated with increasing concentrations of L-DM1-methyl, a more potent analog of Lys-MCC-DM1. These data revealed microtubule thickening/elongation and reduced proplatelet extension (Fig. 5) , which are characteristic of T-DM1 treatment, and confirm that DM1 can disrupt microtubule organization at the earliest stage of platelet production.
To determine if physiological plasma concentrations of T-DM1 activate platelets, mouse and human washed platelets were treated with 100 µg/mL T-DM1, 5B6-DM1, or a vehicle
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From control for 4 hrs. and examined by flow cytometry. While platelets treated with the vehicle control remained discoid, both T-DM1 and 5B6-DM1-treated platelets showed aberrant morphologies as demonstrated by their forward-and side-scatter parameters by flow cytometry (Fig. 6A) . P-selectin surface expression is a classical marker of platelet activation that marks them for clearance by professional phagocytes in the blood. Platelets treated with either T-DM1 or 5B6-DM1 ex vivo demonstrated normal surface expression of P-selectin under resting conditions and on activation with thrombin (Fig. 6B) . Since the parent molecule of DM1, maytansine has been shown to bind microtubules in a manner similar to that of vinca alkaloids 21 we examined platelets from healthy donors for microtubule defects under resting conditions and on contact activation with glass by immunofluorescence microscopy. Interestingly, human platelets formed tennis racket shapes, and revealed less uniformity in platelet diameter when incubated with either T-DM1 or 5B6-DM1 relative to the vehicle control (Fig. 7) . Although platelet clearance may also contribute to thrombocytopenia, mouse and human platelets did not express classical biomarkers of activation following incubation with T-DM1 (Fig. 6B) .
Moreover, platelets showed normal spreading and microtubule depolymerization on contact with glass, suggesting that T-DM1 is not affecting activation. These data predict that T-DM1 decreases platelet counts by targeting proplatelet production and elucidate a mechanism by which thrombocytopoesis is inhibited.
Discussion
This manuscript establishes a novel high-content, quantitative, live-cell imaging assay using the Incucyte system to measure the rate and extent of proplatelet production under live culture conditions for extended periods of time. We then apply this assay to a clinically relevant case of experiment not otherwise amenable to biological replicate analysis. Lastly, by storing and harvesting normally discarded useful information for future elaboration, this assay permits virtual secondary screens for unexpected readouts to be performed after the initial screen. From the same dataset we were able to measure the extent of microtubule branching and thickness
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From using images collected in both brightfield and fluorescent channels after observing disrupted proplatelet production by morphological analysis. These advances have allowed us to study the effect of drug-induced thrombocytopenia on platelet production in multiple sample replicates under high-throughput experimental conditions. An innovative approach to the treatment of cancer is the use of targeted therapies to preferentially deliver cytotoxic chemotherapy to malignant cells. Declines in platelet levels occurred in almost all patients receiving T-DM1 at doses > 1.2 mg/kg, beginning as soon as 1 day after administration and reaching their nadir by approximately Day 8, suggesting that T-DM1 treatment may be affecting platelet production. Indeed, T-DM1 was taken up by cultured mouse megakaryocytes and mouse/human platelets, and DM1 was shown to target microtubule organization in these cells. Platelet activation was not measurably affected, and patients receiving T-DM1 have not presented with clinically significant bleeding events, which support these observations. 15, 26 While megakaryocytes and platelets do not express EGFR, HER2 or HER3 surface receptors, 24, 27 both take up T-DM1 despite also lacking the Fc γ RIIA receptor, suggesting that T-DM1 is endocytosed through an alternative pathway. 18, 28, 29 On entering mouse megakaryocytes DM1 was shown to disrupt the microtubule cytoskeleton and completely inhibit proplatelet production-possibly contributing to thrombocyopenia in patients.
Defining the pathways by which therapeutics such as T-DM1 affect megakaryocyte differentiation and proplatelet-production may yield strategies to manage drug-induced 
